Privacy preference
MEDtalks would like to keep you informed about the content that is most relevant to you. Click
here
for more information.
Yes
No
Back
ASH 2019: azacitidine ± durvalumab bij AML en high risk MDS
Chat with us
, powered by
LiveChat